425: Quanterix Invests Up to $30 Million in Akoya Biosciences via Convertible Notes

Quanterix Corporation has entered into a securities purchase agreement with Akoya Biosciences, Inc., providing up to $30 million in convertible promissory notes to support Akoya's working capital needs pending a potential merger.

Summary

• Quanterix Corporation has agreed to invest up to $30 million in Akoya Biosciences, Inc. through a securities purchase agreement.
• The investment will be in the form of convertible promissory notes, drawn down in one or more tranches.
• Akoya may draw on the Convertible Notes between May 15, 2025 and July 9, 2025, or until January 9, 2026 if the merger agreement termination date is extended.
• The convertible notes will mature 91 days after the earlier of November 1, 2027, or the date Akoya's existing loan agreement is repaid in full.
• The notes bear interest at SOFR plus an applicable margin, payable monthly.
• Quanterix has the option to convert the notes into Akoya common stock if the merger agreement is terminated.
• Conversion is capped at 19.99% of Akoya's common stock prior to stockholder approval.
• Akoya must file a registration statement for the resale of shares issuable upon conversion by August 13, 2025.
• The convertible notes will be subordinate to Akoya's existing debt with MidCap Financial Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The agreement provides Akoya with needed capital, and Quanterix has structured the investment with potential upside. However, risks remain regarding the merger's completion and Akoya's ability to repay the debt.

Positives

• Akoya gains access to up to $30 million in funding to support working capital.
• Quanterix secures a potential return on investment through interest payments and potential stock conversion.
• The agreement includes customary protections for Quanterix, such as operating covenants and events of default.

Negatives

• Akoya takes on additional debt, which could impact its financial flexibility.
• Quanterix faces the risk of non-repayment if Akoya's financial situation deteriorates.
• The conversion of notes into stock is capped at 19.99% without stockholder approval, potentially limiting Quanterix's upside.

Risks

• The merger agreement could be terminated, triggering Quanterix's right to convert the notes.
• Akoya may be unable to repay the convertible notes.
• The value of Akoya's common stock could decline, reducing the potential return on conversion.
• The Nasdaq 19.99% cap could limit the number of shares Quanterix can acquire without stockholder approval.
• The anticipated benefits and synergies of the Merger are not realized when expected or at all.

Future Outlook

The document outlines a potential investment by Quanterix in Akoya, contingent on certain conditions and timelines related to a proposed merger. The future depends on the closing of the merger or, if terminated, on Quanterix's decision to convert the notes into Akoya stock.

Industry Context

This announcement reflects a strategic financial maneuver within the life sciences industry, where companies often seek funding through convertible notes to bridge gaps or facilitate mergers and acquisitions. The investment provides Akoya with financial support while Quanterix gains potential equity in a related business.

Comparison to Industry Standards

• Convertible note financing is a common practice in the biotech and life sciences industries, often used to fund operations or acquisitions.
• Comparable companies like Adaptive Biotechnologies and NanoString Technologies have utilized similar financing structures.
• The interest rate (SOFR plus a margin) and conversion terms are typical for this type of agreement, but the specifics depend on the company's credit profile and the overall market conditions.
• The subordination agreement is standard practice when a company has existing debt, ensuring that senior lenders are prioritized in repayment.

Stakeholder Impact

• Akoya's shareholders may experience dilution if the notes are converted into common stock.
• Akoya's employees benefit from the company's increased financial stability.
• Quanterix's shareholders are exposed to the risks and potential rewards of the investment in Akoya.
• Akoya's customers and suppliers benefit from the company's continued operations.

Next Steps

• Akoya needs to draw on the convertible notes if needed during the draw period.
• Akoya must file a registration statement for the resale of shares issuable upon conversion by August 13, 2025.
• Quanterix and Akoya will need to monitor the progress of the merger agreement.
• If required, Akoya will need to seek stockholder approval for the conversion of notes exceeding the Nasdaq 19.99% cap.

Key Dates

Keywords

Quanterix, Akoya Biosciences, convertible notes, securities purchase agreement, merger agreement, financing, investment, private placement, SOFR, registration rights, subordination agreement